Greenwich LifeSciences, Inc.
Support and Resistance Levels
Past performance
News About GLSI
All events for GLSI
All deals for GLSI
Financial Ratios
Financial Statements
GLSI vs Sector & Peers
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018. Website greenwichlifesciences.com
Headquarters Stafford, TX, US